Infliximab is a chimeric monoclonal antibody biologic. Individuals with psoriasis may develop neutralizing antibodies against monoclonal antibodies. Nivolumab is a fully human monoclonal immunoglobulin G4 antibody to PD-1. Cetuximab and panitumumab are examples of monoclonal antibody inhibitors. Multiple myeloma can be treated with daratumumab (Darzalex) monoclonal antibody. Majority of these monoclonal antibodies are humanized IgG1. Monoclonal antibodies are directed towards exactly defined antigens. Bevacizumab is in the angiogenesis inhibitor and monoclonal antibody families of medication. Chemically, it is a form of a humanized monoclonal antibody. More specific Coombs reagents or monoclonal antibodies can be used. Biopharmaceuticals, such as monoclonal antibodies, differ biologically from small molecule drugs. Pharmaceutical drugs that may cause ILI include many biologics such as interferons and monoclonal antibodies. Libraries of genes and monoclonal antibodies are maintained in phages. HER2 is the target of the monoclonal antibody trastuzumab (marketed as Herceptin). In 1996, Lonza acquired Celltech Biologics and began producing mammalian cell cultures and monoclonal antibodies.